Amneal Pharmaceuticals (Nasdaq:AMRX) - Prezzo delle azioni, notizie e analisi

AMRX Panoramica delle azioni

AMRX analisi fondamentale
Punteggio fiocco di neve
Valutazione	6/6
Crescita futura	1/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Negoziato a 80.6% al di sotto della nostra stima del suo valore equo

Negoziato a un buon valore rispetto ai pari e al settore

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 24.4%

Analisi del rischio

Patrimonio netto negativo

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Amneal Pharmaceuticals, Inc. Concorrenti

Bausch Health Companies

NYSE:BHC

US$3.0b

Perrigo

NYSE:PRGO

US$3.7b

Supernus Pharmaceuticals

NasdaqGM:SUPN

US$2.0b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Amneal Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$8.44
Massimo di 52 settimane	US$9.48
Minimo di 52 settimane	US$4.16
Beta	1.17
1Variazione di 1 mese	-0.35%
Variazione a 3 mesi	4.84%
Variazione di 1 anno	89.66%
3Variazione a 3 anni	82.68%
Variazione a 5 anni	157.32%
Variazione dall'IPO	-43.77%

Notizie e aggiornamenti recenti

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10

Recent updates

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Nov 10

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 10

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Apr 15

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Mar 19

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Dec 28

These 4 Measures Indicate That Amneal Pharmaceuticals (NYSE:AMRX) Is Using Debt Extensively

Apr 18

Amneal Pharmaceuticals: Risk Still Persists

Jan 23

Amneal Pharma reaffirms 2022 guidance

Jan 10

Amneal joins hands with Orion to commercialize generic products in Europe and more countries

Jan 04

Here's Why Amneal Pharmaceuticals (NYSE:AMRX) Is Weighed Down By Its Debt Load

Dec 20

Amneal Pharmaceuticals large shareholder TPG cuts stake

Dec 14

FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203

Nov 11

Amneal Pharmaceuticals Q3 2022 Earnings Preview

Nov 03

Amneal Pharmaceuticals: A Small 'Thumbs Up'

Oct 28

Amneal Pharmaceuticals (NYSE:AMRX) Has A Somewhat Strained Balance Sheet

Sep 01

Amneal Pharma submits NDA for novel formulation of Parkinson's disease treatment

Aug 31

Amneal Pharmaceuticals Q2 2022 Earnings Preview

Aug 04

Rendimenti per gli azionisti

	AMRX	US Pharmaceuticals	US Mercato
7D	-6.5%	-5.3%	-1.2%
1Y	89.7%	8.7%	30.4%

Ritorno vs Industria: AMRX ha superato il US Pharmaceuticals che ha restituito 8.7 % nell'ultimo anno.

Rendimento vs Mercato: AMRX ha superato il mercato US che ha restituito 30.4 % nell'ultimo anno.

Volatilità dei prezzi

Is AMRX's price volatile compared to industry and market?
AMRX volatility
AMRX Average Weekly Movement	4.1%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: AMRX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di AMRX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2002	7,850	Chirag Patel	amneal.com

Amneal Pharmaceuticals, Inc. insieme alle sue consociate, sviluppa, produce, commercializza e distribuisce in tutto il mondo farmaci generici, iniettabili, biosimilari e specialità farmaceutiche di marca. L'azienda opera attraverso tre segmenti: Generici, Specialità e AvKARE. Il segmento Generics offre prodotti orali solidi, in polvere, liquidi, iniettabili sterili, spray nasali, inalatori e respiratori, biosimilari, oftalmici, film, cerotti transdermici e prodotti topici a rilascio immediato ed esteso.

Amneal Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Amneal Pharmaceuticals con la sua capitalizzazione di mercato?
AMRX statistiche fondamentali
Capitalizzazione di mercato	US$2.62b
Guadagni(TTM)	-US$184.45m
Ricavi(TTM)	US$2.68b

1.0x

Rapporto P/S

-14.2x

Rapporto P/E

AMRX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AMRX Conto economico (TTM)
Ricavi	US$2.68b
Costo del fatturato	US$1.70b
Profitto lordo	US$979.05m
Altre spese	US$1.16b
Guadagni	-US$184.45m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.60
Margine lordo	36.53%
Margine di profitto netto	-6.88%
Rapporto debito/patrimonio netto	-7,524.6%

Come si è comportato AMRX nel lungo periodo?

Vedi performance storica e confronto

AMRX Panoramica delle azioni

Premi

Analisi del rischio

Amneal Pharmaceuticals, Inc. Concorrenti

NYSE:BHC

US$3.0b

NYSE:PRGO

US$3.7b

NasdaqGM:SUPN

US$2.0b

NasdaqGS:AMPH

US$2.1b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Senior VP notifies of intention to sell stock

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Recent updates

Senior VP notifies of intention to sell stock

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold US$775k worth of stock

Insider notifies of intention to sell stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold US$256k worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$8.25

New major risk - Negative shareholders equity

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Price target increased by 7.3% to US$7.31

Does Amneal Pharmaceuticals (NASDAQ:AMRX) Have A Healthy Balance Sheet?

Insider exercised options and sold US$332k worth of stock

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 17%

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Stock Catapults 46% Though Its Price And Business Still Lag The Industry

Amneal Pharmaceuticals: By Most Measures, A Fundamentally Undervalued Company

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

New major risk - Financial position

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals: A High-Wire Act Between Growth And Debt

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Is Amneal Pharmaceuticals (NYSE:AMRX) Using Too Much Debt?

Price target increased by 50% to US$5.25

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals Could Have An Upbeat Q2

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Consensus EPS estimates fall by 25%

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

Price target decreased by 18% to US$3.50

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind